
Annual report 2025
added 03-31-2026
BioSig Technologies EPS Ratio 2011-2026 | BSGM
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio BioSig Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.65 | -0.75 | -3.95 | -6.33 | - | -1.87 | -1.65 | -1.25 | -0.5 | -0.6 | -0.7 | -0.91 | -1.23 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.5 | -9.65 | -2.45 |
Quarterly EPS Ratio BioSig Technologies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.47 | -0.74 | -0.14 | - | -0.12 | -0.3 | -0.36 | - | -0.61 | -1.58 | -1.19 | - | -0.14 | - | - | - | -0.21 | -0.24 | -0.26 | - | -0.38 | -0.72 | -0.46 | - | -0.25 | -0.38 | -0.33 | - | -0.22 | -0.44 | -0.25 | - | -0.17 | -0.12 | -0.14 | - | -0.08 | -0.32 | -0.15 | - | 0.02 | -0.35 | -0.26 | - | -0.39 | -0.1 | -0.14 | - | -0.33 | -0.23 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.02 | -1.58 | -0.349 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Medical devices industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
5.63 | $ 176.83 | 5.97 % | $ 13.2 B | ||
|
Alphatec Holdings
ATEC
|
-0.96 | $ 11.66 | 5.71 % | $ 1.75 B | ||
|
Acutus Medical
AFIB
|
-2.81 | - | -26.83 % | $ 2.62 M | ||
|
AxoGen
AXGN
|
-0.34 | $ 34.0 | 9.71 % | $ 1.57 B | ||
|
AdaptHealth Corp.
AHCO
|
-0.52 | $ 12.18 | 2.01 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
-0.48 | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
-6.99 | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
-25.6 | $ 281.15 | 1.13 % | $ 7.93 B | ||
|
Cardiovascular Systems
CSII
|
-0.94 | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
-0.13 | $ 0.62 | 1.67 % | $ 38.6 M | ||
|
Bruker Corporation
BRKR
|
0.76 | $ 38.25 | 4.31 % | $ 5.7 K | ||
|
Boston Scientific Corporation
BSX
|
1.96 | $ 62.56 | 1.15 % | $ 92.6 B | ||
|
Dynatronics Corporation
DYNT
|
-1.43 | - | 14.99 % | $ 929 K | ||
|
Apollo Endosurgery
APEN
|
-0.98 | - | - | $ 475 M | ||
|
Electromed
ELMD
|
0.89 | $ 24.4 | 2.61 % | $ 206 M | ||
|
Second Sight Medical Products
EYES
|
-0.43 | - | -0.97 % | $ 54.4 M | ||
|
ClearPoint Neuro
CLPT
|
-0.9 | $ 9.17 | 1.1 % | $ 260 M | ||
|
GBS
GBS
|
-2 | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
3.98 | $ 91.96 | 2.13 % | $ 12.4 B | ||
|
Avinger
AVGR
|
-23.3 | - | -20.74 % | $ 369 K | ||
|
Inogen
INGN
|
-0.86 | $ 6.67 | -1.91 % | $ 177 M | ||
|
Inspire Medical Systems
INSP
|
4.95 | $ 53.38 | -1.89 % | $ 1.57 B | ||
|
Axonics Modulation Technologies
AXNX
|
-1.28 | - | - | $ 3.31 B | ||
|
IRIDEX Corporation
IRIX
|
-0.26 | $ 1.03 | - | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
2.96 | $ 87.48 | 2.78 % | $ 3.04 B | ||
|
Invacare Corporation
IVC
|
-0.54 | - | - | $ 24.7 M | ||
|
Aziyo Biologics
AZYO
|
1.29 | - | 1.37 % | $ 20.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-1.69 | $ 16.01 | 1.59 % | $ 376 M | ||
|
LivaNova PLC
LIVN
|
-4.45 | $ 64.66 | 1.76 % | $ 3.53 B | ||
|
LENSAR
LNSR
|
-2.87 | $ 5.53 | -1.78 % | $ 66.1 M | ||
|
Butterfly Network
BFLY
|
-0.34 | $ 4.14 | 2.22 % | $ 876 M | ||
|
EDAP TMS S.A.
EDAP
|
-0.57 | $ 3.37 | -0.88 % | $ 126 M | ||
|
Myomo
MYO
|
-0.37 | $ 0.68 | 0.44 % | $ 28.5 M | ||
|
NanoVibronix
NAOV
|
-13.7 | - | - | $ 1.08 M | ||
|
BIOLASE
BIOL
|
-29.4 | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
0.08 | $ 9.85 | 1.86 % | $ 353 M | ||
|
Natus Medical Incorporated
NTUS
|
0.39 | - | 1.94 % | $ 1.05 B | ||
|
Nevro Corp.
NVRO
|
-3.06 | - | - | $ 217 M |